TrialClinical lymphoma, myeloma & leukemia2021

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.

Matthew J Matasar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.